3.連結財務諸表及び主な注記
(1)連結財政状態計算書
| | (単位:百万円) |
| 前連結会計年度 (2024年12月31日) | 当連結会計年度 (2025年12月31日) |
資産 | | |
流動資産 | | |
現金及び現金同等物 | 886 | 1,387 |
営業債権及びその他の債権 | 232 | 374 |
棚卸資産 | 128 | 112 |
その他の流動資産 | 19 | 15 |
流動資産合計 | 1,266 | 1,890 |
非流動資産 | | |
有形固定資産 | 19 | 16 |
使用権資産 | 28 | 97 |
持分法で会計処理されている投資 | 1 | - |
その他の金融資産 | 46 | 141 |
非流動資産合計 | 96 | 254 |
資産合計 | 1,362 | 2,145 |
| | |
負債及び資本 | | |
負債 | | |
流動負債 | | |
営業債務及びその他の債務 | 121 | 229 |
リース負債 | 25 | 31 |
その他の流動負債 | 47 | 51 |
流動負債合計 | 193 | 312 |
非流動負債 | | |
繰延税金負債 | 0 | 5 |
リース負債 | 0 | 64 |
その他の非流動負債 | 10 | 11 |
非流動負債合計 | 12 | 80 |
負債合計 | 206 | 393 |
資本 | | |
資本金 | 2,211 | 836 |
資本剰余金 | 2,255 | 1,455 |
利益剰余金 | △3,277 | △521 |
自己株式 | △65 | △65 |
その他の資本の構成要素 | 33 | 47 |
資本合計 | 1,156 | 1,752 |
負債及び資本合計 | 1,362 | 2,145 |
E3304445970ソレイジア・ファーマ株式会社Solasia Pharma K.K.通期第3号参考様式 [IFRS](連結)IFRStrueCTECTE2025-01-012025-12-31FY2025-12-312024-01-012024-12-312024-12-311falsefalsefalse459702025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-01-012025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-01-012024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702023-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-12-31jpigp_cor:ShareCapitalIFRSMember459702025-01-012025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-01-012025-12-31jpigp_cor:TreasurySharesIFRSMember459702025-01-012025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-01-012025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-01-012025-12-31jpigp_cor:ShareCapitalIFRSMember459702024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-12-31jpigp_cor:ShareCapitalIFRSMember459702024-01-012024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-01-012024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-01-012024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-01-012024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-01-012024-12-31jpigp_cor:ShareCapitalIFRSMember459702023-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-02-13459702025-12-31459702025-01-012025-12-31459702024-12-31459702024-01-012024-12-31459702023-12-31459702023-12-31jpigp_cor:TreasurySharesIFRSMember459702023-12-31jpigp_cor:RetainedEarningsIFRSMember459702023-12-31jpigp_cor:CapitalSurplusIFRSMember459702023-12-31jpigp_cor:ShareCapitalIFRSMember459702025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-01-012025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702024-01-012024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702023-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702025-01-012025-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702024-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702024-01-012024-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702023-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-12-31jpigp_cor:TreasurySharesIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure